CPI-613 is an E1α pyruvate dehydrogenase (PDH) modulator that prevents cancer cells from metabolizing glucose for energy. CPI-613 has been granted orphan drug status by the US FDA for pancreatic cancer.
More Information Supplier Page
CPI-613 is an E1α pyruvate dehydrogenase (PDH) modulator that prevents cancer cells from metabolizing glucose for energy. CPI-613 has been granted orphan drug status by the US FDA for pancreatic cancer.
More Information Supplier Page CPI-613 is an E1α pyruvate dehydrogenase (PDH) modulator that prevents cancer cells from metabolizing glucose for energy. CPI-613 has been granted orphan drug status by the US FDA for pancreatic cancer.
More Information Supplier Page CPI-613 is an E1α pyruvate dehydrogenase (PDH) modulator that prevents cancer cells from metabolizing glucose for energy. CPI-613 has been granted orphan drug status by the US FDA for pancreatic cancer.
More Information Supplier Page 
Diatrizoic acid is an organic, iodinated radiopaque X-ray contrast medium used in diagnostic radiography.
More Information Supplier Page
Diatrizoic acid is an organic, iodinated radiopaque X-ray contrast medium used in diagnostic radiography.
More Information Supplier Page 
Limonin is a naturally occuring furanolactone which can inhibit the HIV-1 replication.
More Information Supplier Page
Limonin is a naturally occuring furanolactone which can inhibit the HIV-1 replication.
More Information Supplier Page 
JNK Inhibitor IX can selectively inhibit JNK2 and JNK3 through targeting the ATP binding site with pIC50 of 6.5 and 6.7, respectively.
More Information Supplier Page
JNK Inhibitor IX can selectively inhibit JNK2 and JNK3 through targeting the ATP binding site with pIC50 of 6.5 and 6.7, respectively.
More Information Supplier Page 
